Brief: Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria
20/09/2026 11:03
BRIEF-Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria Sept 20 (Reuters) - Cue Biopharma, Inc. CUE.O:
CUE BIOPHARMA ANNOUNCES POSITIVE TOPLINE RESULTS FROM CUE-221 PHASE 2 STUDY IN CHRONIC SPONTANEOUS URTICARIA
CUE BIOPHARMA, - PHASE 2 PRIMARY AND KEY SECONDARY ENDPOINTS MET
Source text: ID:nGNXYm9rX
Further company coverage: CUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cue Biopharma
See all newsU.S. STOCKS ON THE MOVE-Insmed, Marvell, Meta
US STOCKS ON THE MOVE-Meta, Marvell Technology, Insmed
U.S. STOCKS ON THE MOVE-Accenture, Arhaus, Alkermes
Cue Biopharma surges after positive results from mid-stage study for CUE-221
Brief: Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria